



In Person + Live Streaming  
**TTS 2024** ISTANBUL TURKEY  
September 22-25  
+ Virtual October 21-23

Organized in partnership with



Endorsed by

# Clinical characteristics of lupus nephritis patients submitted to kidney transplantation in a single center

**Beatriz Pachi, Laura Bischoff, Luísa Borba, Helena Bischoff, Gisele Meinerz, Elizete Keitel**

**Santa Casa de Porto Alegre, RS, Brazil / Universidade Federal de Ciências da Saúde de Porto Alegre, RS, Brazil**




In Person + Live Streaming  
**TTS 2024** ISTANBUL TURKEY  
September 22-25  
+ Virtual October 21-23

Organized in partnership with



Endorsed by

**The authors have no conflict of interests to disclose.**





In Person + Live Streaming  
**TTS 2024** ISTANBUL TURKEY  
September 22-25  
+ Virtual October 21-23

Organized in partnership with



Endorsed by

## Background and Objectives:

- **Lupus Nephritis (LN) affects approximately 50% of patients with Systemic Lupus Erythematosus (SLE)**
- **can lead to end-stage renal disease requiring kidney transplantation**

## Methodology:

- **Retrospective cohort of 99 kidney transplant recipients due to LN from 1977 to 2023 in a single center.**



In Person + Live Streaming

# TTS 2024

ISTANBUL TURKEY  
September 22-25  
+ Virtual October 21-23


Organized in partnership with




Endorsed by

99


patients



83% first graft



86.9% female



22% recorded LN class  
18% class IV

AGE+

20y at SLE diagnosis  
30y at kidney transplant



medians:  
10y from SLE diagnosis  
1.3y on dialysis



60% white  
20% mixed race



In Person + Live Streaming


# TTS 2024

ISTANBUL TURKEY  
September 22-25  
+ Virtual October 21-23


Organized in partnership with




Endorsed by




**infections:**  
**65% bacterial**  
**35% viral**




**44% on follow-up**  
**38% graft loss**  
**13% death**



**16% neoplasms**



**graft losses:**  
**6% thrombosis**  
**6% infection**  
**25% rejection**  
**none due to LN**



**46% had graft biopsies**  
**26% rejection**  
**5% recurrence**



**5% cardiovascular**  
**2% neoplasm**  
**6% infection**



In Person + Live Streaming  
**TTS 2024** ISTANBUL TURKEY  
September 22-25  
+ Virtual October 21-23

Organized in partnership with



Endorsed by

- **5-year graft survival was 71.6%**
- **HLA DR15 was associated with a higher risk of graft loss  
(HR 3.34 CI 95% 1.06 - 10.57, p = 0.040)**
- **Male sex was associated with a higher risk of graft loss  
(HR 4.21 CI 95% 1.08 - 16.38, p = 0.038)**



In Person + Live Streaming  
**TTS 2024** ISTANBUL TURKEY  
September 22-25  
+ Virtual October 21-23

Organized in partnership with



Endorsed by

## Conclusions:

- We presented the clinical characteristics and outcomes of 99 patients with LN submitted to KT.
- Post-transplant graft survival was similar to that of kidney transplants for other causes at this institution.
- The presence of HLA DR 15 and male sex were associated with greater risk of graft loss our LN patients.